Radiology

New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team

MINNEAPOLIS, Aug. 13, 2025 /PRNewswire/ — A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all…

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of […]

Sirtex Medical’s SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of…

MultiFunctional Imaging Announces Journal Of Nuclear Cardiology Publication Detailing Rapid Myocardial Perfusion Imaging

Data demonstrates MFI’s propriety software enables 15 minute immediate back-to-back Rest- Stress scanning with Flyrcadoä radiotracer SOUTH OGDEN, UT – June 20, 2025 –- MultiFunctional Imaging LLC (MFI) today announced the publication of data submitted to the Journal of Nuclear Cardiology (JNC), a leading peer-reviewed journal. The study validates MFI’s […]

ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium

Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from June 21 – June 24, 2025 in New Orleans, Louisiana. Details of the Oral PresentationThe data will be presented by Dr. Thomas A. Hope, MD, Chief of Nuclear Medicine at the San Francisco VA Medical Center and Vice Chair of Clinical Operations and Strategy in the Department of Radiology at UCSF in an oral presentation titled, “Predicting the [177Lu]Lu-edotreotide uptake in tumors using pre-therapeutic Ga-68 PET/CT imaging”, on Sunday, June 22 in the Neuroendocrine – Oncology Clinical Diagnosis and Therapy session from 3:30 – 4:45 pm CDT. The presentation will provide an analysis on the 177Lu-edotreotide tumor uptake and its predictability based on pre-therapeutic SSTR PET/CT imaging and other factors.

CIVIE Launches RadPod, an AI-Empowered On-Demand Radiology Reading Platform

DALLAS–(BUSINESS WIRE)–CIVIE, a leading healthcare technology and services company, today announces the official launch of RadPod, an AI-driven, on-demand radiology platform designed to transform how, when and where radiologists work. RadPod was developed to align the interests of radiologists, hospital systems and the latest in healthcare technology to ensure the practice of […]